ZA83173B - Ascorbic acid ethers and compounds - Google Patents

Ascorbic acid ethers and compounds

Info

Publication number
ZA83173B
ZA83173B ZA83173A ZA83173A ZA83173B ZA 83173 B ZA83173 B ZA 83173B ZA 83173 A ZA83173 A ZA 83173A ZA 83173 A ZA83173 A ZA 83173A ZA 83173 B ZA83173 B ZA 83173B
Authority
ZA
South Africa
Prior art keywords
compounds
ascorbic acid
acid ethers
ethers
ascorbic
Prior art date
Application number
ZA83173A
Other languages
English (en)
Inventor
Gary Allen Koppel
Lavern Barton Russell
Jesse Robert Bewley
Stephen Lyle Briggs
Joseph Wayne Parton
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA83173B publication Critical patent/ZA83173B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62Three oxygen atoms, e.g. ascorbic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA83173A 1982-01-15 1983-01-11 Ascorbic acid ethers and compounds ZA83173B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33934482A 1982-01-15 1982-01-15

Publications (1)

Publication Number Publication Date
ZA83173B true ZA83173B (en) 1984-08-29

Family

ID=23328588

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA83173A ZA83173B (en) 1982-01-15 1983-01-11 Ascorbic acid ethers and compounds

Country Status (16)

Country Link
EP (1) EP0086554A1 (xx)
JP (1) JPS58131978A (xx)
KR (1) KR840003247A (xx)
AU (1) AU1035183A (xx)
CA (1) CA1181078A (xx)
DD (1) DD209455A5 (xx)
DK (1) DK14283A (xx)
ES (2) ES8403118A1 (xx)
FI (1) FI830078L (xx)
GB (1) GB2114571A (xx)
GR (1) GR77897B (xx)
IL (1) IL67646A0 (xx)
PL (1) PL240125A1 (xx)
PT (1) PT76083B (xx)
RO (1) RO86439B (xx)
ZA (1) ZA83173B (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552895A (en) * 1983-03-14 1985-11-12 Eli Lilly And Company Furo[3,2-b]furan-2-(3H)-ones
JPS6058973A (ja) * 1983-09-13 1985-04-05 Mitsubishi Yuka Yakuhin Kk γ−プチロラクトン誘導体及びそれを有効成分とする免疫調節剤
JPS60130582A (ja) * 1983-12-19 1985-07-12 Takeda Chem Ind Ltd 食品用酸化防止剤,アスコルビン酸誘導体およびその製造法
WO1986006720A1 (en) * 1985-05-17 1986-11-20 Takeda Chemical Industries, Ltd. Ascorbic acid derivatives, production thereof, and pharmaceutical preparation therefrom
WO1986007592A1 (en) * 1985-06-18 1986-12-31 Takeda Chemical Industries, Ltd. Ascorbic acid derivatives, process for their preparation, and preparations containing same
JPS60139619A (ja) * 1983-12-27 1985-07-24 Mutsuyuki Kochi O−ベンジリデン−アスコルビン酸又はその塩よりなる抗腫瘍剤
JP2515556B2 (ja) * 1986-08-29 1996-07-10 武田薬品工業株式会社 ヒドロキシブテノライド誘導体およびその製造法
JP2752080B2 (ja) * 1988-03-09 1998-05-18 株式会社日本ハイポックス アスコルビン酸誘導体及びその製造方法並びにアスコルビン酸誘導体からなる抗酸化剤
JPH0730066B2 (ja) * 1988-03-09 1995-04-05 株式会社日本ハイポックス アスコルビン酸誘導体及びアスコルビン酸誘導体からなる抗酸化剤
DE68927904T2 (de) 1988-09-01 1997-09-04 Takeda Chemical Industries Ltd Fumagillol-Derivate
WO1991003471A1 (fr) * 1989-09-11 1991-03-21 Nippon Hypox Laboratories Incorporated Derives d'acide ascorbique
US5095126A (en) * 1990-01-12 1992-03-10 Ohio State University Research Foundation Efficient synthesis for optically pure stereogenically labile 4-substituted-2-hydroxytetronic acids
ATE125814T1 (de) * 1990-03-07 1995-08-15 Hoffmann La Roche Verfahren zur herstellung von derivaten der ascorbinsäure.
US5270336A (en) * 1990-03-16 1993-12-14 Merrell Dow Pharmaceuticals Inc. Ascorbic acid derivatives
EP0446539A1 (en) * 1990-03-16 1991-09-18 Merrell Dow Pharmaceuticals Inc. Novel ascorbic acid derivatives
JPH0429989A (ja) * 1990-05-24 1992-01-31 Nisshin Flour Milling Co Ltd L―アスコルビン酸誘導体の製造法
GB9026114D0 (en) * 1990-11-30 1991-01-16 Norsk Hydro As New compounds
GB9201274D0 (en) * 1992-01-21 1992-03-11 Norsk Hydro As New compounds
GB9201275D0 (en) * 1992-01-21 1992-03-11 Norsk Hydro As New compounds
TW325997B (en) * 1993-02-02 1998-02-01 Senju Pharma Co Pharmaceutical composition for preventing and treating retinal diseases
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US6114355A (en) * 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
JP2002513391A (ja) 1996-11-05 2002-05-08 ザ チルドレンズ メディカル センター コーポレイション 血管形成の抑制のための方法と組成物
EP0875246A1 (en) * 1997-04-04 1998-11-04 Showa Denko Kabushiki Kaisha Pharmaceutical preparation of ascorbic acid derivatives for medical treatment of cancer
CA2324306C (en) * 1998-03-27 2005-05-24 Lg Chemical Ltd. Polyethoxylated ascorbic acid derivatives as a novel antioxidant and process for preparing thereof
US6673828B1 (en) 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
AU2001230554A1 (en) * 2000-02-01 2001-08-14 Mutsuyuki Kochi Neovascularization inhibitory compositions and method of inhibiting neovascularization
CZ20023231A3 (cs) * 2000-03-31 2003-01-15 Angiogene Pharmaceuticals Ltd. Farmaceutické prostředky obsahující činidla poąkozující cévy
ES2261458T3 (es) * 2001-07-26 2006-11-16 Tagra Biotechnologies Ltd Derivados estabilizados del aciddo ascorbico 3-fosfato.
KR100971599B1 (ko) 2002-05-15 2010-07-20 비에이취엔 가부시끼가이샤 혈관 관련 질환의 예방 또는 치료를 위한 조성물
EP1939192A1 (en) * 2006-12-28 2008-07-02 Neuropharma S.A. Cyclopentanone derivatives, method of synthesis and uses thereof
FR2955493B1 (fr) * 2010-01-28 2012-02-24 Oreal Utilisation de derives d'acide ascorbique en coloration des fibres keratiniques humaines, composition les comprenant, procede de coloration et dispositif
JP5602456B2 (ja) * 2010-02-24 2014-10-08 日本精化株式会社 アスコルビン酸誘導体
US9550744B2 (en) * 2013-09-25 2017-01-24 University Of Florida Research Foundation, Inc. Vitamin C prodrugs and uses thereof
US10105407B2 (en) * 2015-06-09 2018-10-23 John P. Crow, JR. Methods of extraction of nitrosylated or nitrated derivatives of ascorbic acid from myriciaria dubia and methods of synthesis thereof
US10583171B2 (en) 2015-11-30 2020-03-10 INSERM (Institut National de la Santé et de la Recherche Médicale) NMDAR antagonists for the treatment of diseases associated with angiogenesis

Also Published As

Publication number Publication date
RO86439A (ro) 1985-03-15
ES518968A0 (es) 1984-03-01
GR77897B (xx) 1984-09-25
FI830078L (fi) 1983-07-16
KR840003247A (ko) 1984-08-20
DD209455A5 (de) 1984-05-09
FI830078A0 (fi) 1983-01-10
DK14283A (da) 1983-07-16
AU1035183A (en) 1983-07-21
DK14283D0 (da) 1983-01-14
GB2114571A (en) 1983-08-24
ES8502698A1 (es) 1985-01-16
GB8300907D0 (en) 1983-02-16
EP0086554A1 (en) 1983-08-24
ES525239A0 (es) 1985-01-16
PT76083A (en) 1983-02-01
ES8403118A1 (es) 1984-03-01
CA1181078A (en) 1985-01-15
JPS58131978A (ja) 1983-08-06
IL67646A0 (en) 1983-05-15
PT76083B (en) 1986-01-09
PL240125A1 (en) 1984-04-24
RO86439B (ro) 1985-03-31

Similar Documents

Publication Publication Date Title
ZA83173B (en) Ascorbic acid ethers and compounds
GB8300312D0 (en) Circuitry
GB8333203D0 (en) Diaper
CS503683A2 (en) Zpusob vyroby (s)-epimeru esteru kyseliny 7beta-malonamido-7alfa-methoxy-3-tetrazolylthiomethyl-1-dethia-1-oxa-3-cefem-4-karboxylove
GB8411259D0 (en) Medicinal agent
GB8313783D0 (en) Bandage constructions
GB8325337D0 (en) Porphylactic substance
DE3366682D1 (en) Substituted pyridyl-phenyl ethers
GB2134737B (en) Amplifier
GB8324194D0 (en) Caster
DE3360685D1 (en) Antimycosic agent
DE3370261D1 (en) Amplifier
GB8308451D0 (en) Amplifier
PH18658A (en) Ethers
DE3361451D1 (en) Fungicidal cyanopropenoates and compositions containing them
YU134983A (en) Comutation amplifier
GB8329265D0 (en) Soil-limiting underpants
IL69094A0 (en) Ointment and its preparation
GB2123413B (en) Eburnane-oxime ethers
GB2119787B (en) Pyrones
GB8306720D0 (en) Amplifier
GB2085443B (en) Calcitroic acid and related compounds
GB2368215B (en) Ranging
GB8314199D0 (en) Axles
GB2119237B (en) Castor